AFP and hepatocellular carcinoma: The only biomarker currently validated for clinical use for screening for HCC, alpha-fetoprotein (AFP), has marginal sensitivity and specificity (approximately 60 and 80%, respectively); not surprisingly, most societal guidelines recommend its use only in combination with abdominal ultrasound [32,34,35,36].